Skip to main content

Table 3 Multivariable analysis for PFS adjusted by treatment and metastatic volume

From: The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study

  HR 95 % CI for HR p-value
Mets Volume (High vs. Low) 2.66 (1.34, 5.27) 0.005
Treatment (ADT + Chemo vs. ADT) 1.09 (0.65, 1.84) 0.75
 Insulin (ln)a (<2.1 vs. ≥2.1) 2.55 (1.24, 5.23) 0.011
 HGF (ln)a (>8.9 vs. ≤8.9) 2.00 (1.08, 3.70) 0.027
 OPN (ln)a (>11.9 vs. ≤11.9) 1.67 (0.84, 3.33) 0.147
C-peptide (ln) (Unit = 1000) 0.97 (0.86, 1.10) 0.622
  1. OPN osteopontin, HGF hepatocyte growth factor
  2. aCut points were determined by CART analysis